Figure 6
From: Expamers: a new technology to control T cell activation
In vivo function of Expamer-stimulated anti-CD19 CAR T cells. (A) CD19+ Raji/ffluc/GFP tumor cells were engrafted for 7 days in NSGS mice, subsequently 0.75 × 106 CAR T cells (bulk) were infused on day 1. (B) Tumor was imaged using IVIS bioluminescence at indicated time points. (C) Average radiance was quantified using Living image. (D and E) Absolute cell count of CAR T cells in blood was calculated using cell count and frequencies gathered from flow-cytometry analysis. Frequency of tumor cells in blood (CD45+/GFP+) was measured via flow-cytometry illustrated over time. Cells were pre-gated on living lymphocytes. (F) Survival analysis of each group is shown. PBS control is shown in grey. Statistical analysis: log-rank Mantel–Cox test; ***P ≤ 0.0007, n = 4 mice per group, total of 12 mice. Means ± SEM are plotted.
